$0.77
−3.15%Price chart
Mar 26Mar 31Apr 6Apr 9Apr 14Apr 17Apr 22Apr 27
Key dataApr 27, 2026
Open$0.98
From 52W high−74.09%
Volume1.71M
Market cap$31.90M
P/E (TTM)9.6x
P/S (TTM)152.6x
Div yield—
Key dataApr 27, 2026
Open
$0.98
From 52W high
−74.09%
Volume
1.71M
Market cap
$31.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
9.6x
RSI (14)
56.2
MomentumView details →
1D Return
−3.15%
YTD Return
−20.27%
SummaryUpdated Jun 1, 2026
Leap Therapeutics, Inc. (NASDAQ:LPTX) is a biopharmaceutical company founded in 2011 and headquartered in Cambridge, Massachusetts. Originally incorporated as HealthCare Pharmaceuticals, Inc., the company rebranded to its current name in November 2015 and went public in January 2017. Leap focuses on acquiring and developing innovative cancer therapies, with its primary asset being DKN-01, a monoclonal antibody currently in multiple clinical trials for various cancer types. The company operates as a clinical-stage biotech with no current revenue, relying on external funding to advance its drug development programs.
Similar companies
Latest newsMore news →
Cypherpunk Technologies Inc. appointed Amanda Fabiano as a Class III independent director effective September 22, 2026, with RSU awards covering 250,000 shares.28d agoCypherpunk Technologies acquired 4,902 Zcash mining machines from Moria Mining, an affiliate of Winklevoss Treasury Investments, for $33.33 million in an equity deal, gaining about 18% of Zcash's mining power.62d agoCypherpunk Technologies launched the world's largest Zcash mining fleet in the U.S. with about 4.2 GSol/s of Equihash hashrate, representing about 18% of the total Zcash network.63d ago